Objective:

To present a case of a patient with initially unresectable intrahepatic cholangiocarcinoma (ICC) treated with a multimodal conversion therapy approach.

Approach:

Key Findings:

• The combination of PVE, surufatinib, sintilimab, and FOLFOX led to significant tumor reduction.
• The patient achieved 28 months of disease-free survival post-surgery.

Interpretation:

Limitations:

• The study is based on a single case report, limiting generalizability.
• Further research with larger sample sizes is necessary to validate findings.

Conclusion:

Conversion therapy using PVE, surufatinib, sintilimab, and FOLFOX can improve the resection rate in patients with initially unresectable ICC.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.